Roswell Park’s Genitourinary Program is teaming up with prostate cancer researchers across the country to expand clinical trial efforts in the search for cures.
Clinical trials can be a researcher’s best tool in the search for new ways to treat cancer. For patients, these trials provide hope for survival when other treatment efforts aren’t working. That’s why Roswell Park’s Genitourinary Program is teaming up with prostate cancer researchers across the country to expand clinical trial efforts in the search for cures.
The Prostate Cancer Clinical Trial Consortium is a nationwide network of physicians and researchers at thirteen academic institutions that are considered additional leaders in prostate cancer research, including Memorial Sloan-Kettering Cancer Center and Dana-Farber Cancer Center. Consortium members work together toward one mission: to design, implement and complete clinical trials in prostate cancer that translate to improved standards of care for patients.
With funding from your donations, Roswell Park will participate in the consortium and, as a result, provide new, promising clinical trial options to more prostate cancer patients than ever.
“With this increased number of clinical trials, more prostate cancer patients will have the chance to try novel treatments,” said Roberto Pili, M.D., Chief of the Genitourinary Section at Roswell Park. “The impact of these expanded investigations—coupled with the resources and expertise we’ll benefit from through the consortium—will greatly accelerate our efforts to find new and better ways to treat prostate cancer.”